12月22日，粤商·省长面对面协商座谈会在广州召开，围绕"以改革创新为动力，推动生物医药产业高质 量发展"主题，企业家代表与省领导和相关部门负责人深入交流，共商高质量建设生物医药强省各方面 工作。省委副书记、省长孟凡利出席并讲话，省政协主席林克庆主持。 会上，一品红集团李捍雄、新济药业吴传斌、华大智造刘心、康方生物李百勇、深圳生物制造产业创新 中心罗巍、微灵医疗李骁健、迈瑞医疗吴昊、广州百济神州王英群、广东三生制药陆宏辉、泛恩生物周 鹏辉、瑞风生物梁峻彬、信立泰药业颜杰等12位粤商代表发言，围绕生物医药产业发展政策与工作措施 积极建言献策。孟凡利认真听取大家发言，不时对企业提出的意见建议予以回应并现场作出安排部署。 孟凡利感谢省政协组织政协机关、政协委员和企业家们聚焦生物医药产业精心举办这场座谈会。他表 示，我省生物医药产业发展基础扎实、势头良好，但也面临着一些短板弱项。要坚持目标导向、问题导 向、结果导向，针对省政协调研报告中指出的问题和企业家提出的建议，逐条逐项清单化研究，尽快形 成翔实的生物医药产业发展明年和"十五五"期间工作方案。要强化企业科技创新主体地位，推动平台、 项目、人才、资金等创新资源全力服 ...

Group 1 - The core agreement between Chengdu High-tech Zone and Sichuan Development (Holding) Company focuses on deep cooperation in the pharmaceutical and health industry, including equity cooperation, fund establishment, talent exchange, and innovation incubation [2] - The collaboration aims to enhance the pharmaceutical health industry in Sichuan Province by building industrial funds, attracting quality projects, and developing professional incubation platforms [2][3] - Chengdu High-tech Zone is recognized as a key area for developing new productive forces, particularly in the pharmaceutical health sector, with plans to strengthen industrial cooperation in biomedicine [2] Group 2 - Since 2022, Chengdu High-tech Zone has been collaborating with Sichuan Development (Holding) Company's subsidiary, Sichuan Biopharmaceutical Group, focusing on investment in chemical drugs, medical devices, and pharmaceutical outsourcing services [3] - The partnership has successfully completed acquisitions, such as Sichuan Biopharmaceutical Group's acquisition of Hongming Bosi Pharmaceutical, and has nurtured several listed companies and local star enterprises [3] - Chengdu High-tech Zone has gathered over 3,900 biopharmaceutical companies and established more than 160 functional platforms covering the entire lifecycle of biopharmaceuticals [4] Group 3 - The capital support service system in Chengdu High-tech Zone includes a full lifecycle model with 24 pharmaceutical health funds totaling 34 billion yuan [4] - The zone has approved 12 Class I new drugs and over 100 Class III medical devices, with more than 80 products valued at over 100 million yuan [4] - Chengdu High-tech Zone has maintained a leading position in the national biopharmaceutical industrial park competitiveness ranking for several years [4]

Core Insights - The fifth China Biopharmaceutical Quality Control Conference highlighted the National Medical Products Administration's (NMPA) comprehensive reform of drug regulation, aimed at enhancing review and approval quality and efficiency, thereby stimulating innovation in the biopharmaceutical sector [1] Regulatory Developments - The NMPA plans to fully implement the State Council's opinions on deepening drug and medical device regulatory reforms to promote high-quality development in the pharmaceutical industry [1] - Future reforms will focus on improving the review and approval system, enhancing regulatory frameworks, and addressing clinical needs [1] Industry Growth - Among the 56 innovative drugs approved for market by 2025, 18 are biopharmaceutical products, indicating a significant presence of biopharmaceuticals in the innovation pipeline [1] - The NMPA aims to support the development of advanced therapeutic drugs and encourage companies to integrate into international innovation and supply chains, promoting high-quality growth in China's biopharmaceutical industry [1]

Core Insights - The biopharmaceutical industry in China is experiencing dual benefits from policy support and accelerated industrial upgrades, with a focus on innovation as the driving force for high-quality development [1][2][3] Policy Guidance - The State Council approved the "China (Jiangsu) Free Trade Zone Biopharmaceutical Full Industry Chain Open Innovation Development Plan," emphasizing high-level openness and institutional innovation to promote integrated innovation across the biopharmaceutical industry chain [2] - The "14th Five-Year Plan" for biopharmaceutical development aims for China to maintain a leading position in global biopharmaceutical strength by 2035, with measures to optimize drug and medical device approval processes [2] - Local policies, such as those from Hubei Province, set ambitious revenue targets for the biopharmaceutical industry, aiming for 250 billion yuan by 2027, focusing on specific sectors like CAR-T therapy [2][3] Technological Breakthroughs - China's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs under development, and 204 innovative drugs and 265 innovative medical devices approved since the start of the "14th Five-Year Plan" [4] - The biopharmaceutical market is projected to reach approximately 2.14 trillion yuan in 2024, with an expected growth rate of 8.12%, increasing to 2.24 trillion yuan by 2025 [4] - Significant technological advancements include the commercialization of "rice-based blood" technology and the launch of a non-invasive test kit for endometrial cancer, showcasing the rapid development of innovative solutions [5][6] Industry Challenges - Despite positive developments, the biopharmaceutical industry faces challenges such as technological bottlenecks and a shortage of skilled talent, which hinder the transition to high-quality development [7][8] - Key areas requiring improvement include original innovation capabilities, reliance on imported high-end equipment, and the need for a more robust talent pool that integrates various disciplines [7][8] Strategic Recommendations - To overcome these challenges, a multi-faceted approach is necessary, including enhancing top-level design, integrating industry-academia-research collaboration, and encouraging increased R&D investment [8] - Optimizing talent cultivation systems and fostering interdisciplinary education are crucial for developing a workforce that meets industry demands [8]

Core Viewpoint - The Hainan provincial government has introduced a series of policy measures to support the high-quality development of the biopharmaceutical industry, leveraging the unique advantages of the Hainan Free Trade Port to create a comprehensive policy support system for the entire industry chain [3]. Group 1: Support for R&D and Innovation - The policy continues to implement a research and development voucher program, providing financial rewards ranging from 400,000 to 10 million yuan based on the stage of product development [3]. - Enterprises participating in national bulk procurement will receive a reward of up to 3% of actual sales, with a maximum of 3 million yuan [3]. - A one-time reward of 2 million yuan will be given to enterprises that achieve international certification [3]. Group 2: Industry Expansion and Upgrading - A reward of 30 million yuan will be provided to municipalities for single projects that have a significant impact on the industry [3]. - The policy encourages mergers and acquisitions of local pharmaceutical companies, offering a 50% interest subsidy on loans for up to 2 years, with a maximum subsidy of 5 million yuan [3]. - New emerging industries such as biomanufacturing, medical beauty, special medical foods, and digital therapy will receive one-time rewards ranging from 200,000 to 1.5 million yuan based on specific criteria [4]. Group 3: Industry Ecosystem and Infrastructure - The policy aims to strengthen the industrial ecosystem by addressing shortcomings in the biopharmaceutical industry chain, including R&D innovation, pilot research, technology transfer, and clinical research [6]. - New or expanded investments of 5 million yuan or more will receive a reward of up to 500,000 yuan, based on 30% of the investment amount [6]. - Annual service amounts exceeding 3 million yuan will be rewarded at 5% of the service amount, with a maximum of 500,000 yuan [6]. Group 4: Internationalization and Talent Development - The policy supports existing enterprises in scaling up and enhancing quality, promoting international development [5]. - It emphasizes the importance of digital, intelligent, and green transformation for industry upgrading [6]. - Initiatives for talent introduction and educational collaboration are included to enhance the industry's influence and foster international cooperation [7].

Group 1 - The article highlights the Hainan Provincial Government's issuance of policies to support the high-quality development of the biopharmaceutical industry [1] - It emphasizes the continuous increase in support for the research and development of innovative drugs and medical devices [1] - The policy includes a funding reward system for product development, offering financial incentives ranging from 400,000 to 10 million yuan based on the stage of achievement in preclinical research, clinical trials, and new product commercialization [1]